Ritu Salani, MD
Obstetrics & Gynecology · Los Angeles, CANPI 1356482905
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $111,370 of the $157,672 with a category attached, or 70.6%. It is spread thinly across 20 manufacturers, the largest accounting for just 21.8%. Among obstetrics & gynecology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $916.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$34K
- GSK$25K
- Seagen Inc.$20K
- Daiichi Sankyo Inc.$18K
- Genmab U.S., Inc.$13K
- Eisai Inc.$12K
- plus $36K from 14 others
Across 51 payments — averaging $11,543 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$352K
- Alkermes, Inc.$147K
- Genentech, Inc.$42K
- AstraZeneca$31K
- Genmab A/s$14K
- Springworks Therapeutics, Inc.$2K
- plus $1K from 1 others
What the payments were for
- Consulting fees$111,37071%
- Speaking & faculty fees$18,87512%
- Travel & lodging$19,08512%
- Food & beverage$8,2775%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 29 | $34,408 |
| GSK | 25 | $25,288 |
| Seagen Inc. | 18 | $20,096 |
| Daiichi Sankyo Inc. | 18 | $17,662 |
| Genmab U.S., Inc. | 11 | $12,649 |
| Eisai Inc. | 5 | $11,576 |
| Regeneron | 8 | $7,276 |
| AstraZeneca | 9 | $7,101 |
| Clovis Oncology, Inc. | 18 | $6,612 |
| Corcept Therapeutics | 10 | $4,273 |
| AbbVie | 4 | $3,207 |
| Pfizer | 4 | $3,095 |
| Aadi Bioscience, Inc. | 1 | $1,867 |
| Karyopharm Therapeutics Inc. | 1 | $1,610 |
| Genentech USA, Inc. | 4 | $313 |
| Tesaro, Inc. | 2 | $250 |
| Medical Device Business Services, Inc. | 2 | $130 |
| Hologic Sales And Service, LLC | 1 | $123 |
| Stemline Therapeutics Inc. | 1 | $101 |
| Johnson & Johnson | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$157,672 in reported general payments places this provider in the 95th percentile of 3,784 obstetrics & gynecology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other obstetrics & gynecology in Los Angeles
- Malcolm MunroLos Angeles$609K
- Ramon YeraLos Angeles$296K
- Aela PaizLos Angeles$131K
- Roy SilverLos Angeles$57K
- Karen MannLos Angeles$50K
- Sebhat AfeworkLos Angeles$42K
- Nicole BenderLos Angeles$35K
- Christine SterlingLos Angeles$30K
- Steve YuNorthridge$964K
- Samir HageRedlands$640K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.